Analyst Price Targets — CNMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 13, 2026 2:09 pm | — | Wells Fargo | $39.00 | $41.98 | TheFly | Wells finds Conmed sale report 'little surprising' after refinance |
| July 8, 2026 8:30 pm | — | BMO Capital | $36.00 | $33.59 | TheFly | Conmed initiated with a Market Perform at BMO Capital |
| May 1, 2025 1:26 pm | Mike Matson | Needham | $61.00 | $57.19 | TheFly | Conmed price target lowered to $61 from $91 at Needham |
| October 4, 2024 9:04 am | Mike Matson | Needham | $97.00 | $66.59 | StreetInsider | Needham Reiterates Buy Rating on CONMED (CNMD) |
| April 25, 2024 9:46 am | Matt O\'Brien | Piper Sandler | $95.00 | $64.34 | StreetInsider | CONMED (CNMD) PT Lowered to $95 at Piper Sandler |
| April 25, 2024 7:28 am | Mike Matson | Needham | $107.00 | $70.01 | StreetInsider | CONMED (CNMD) PT Lowered to $107 at Needham |
| October 26, 2022 8:00 pm | Matt O'Brien | Piper Sandler | $108.00 | $83.39 | TheFly | Conmed price target lowered to $108 from $118 at Piper Sandler |
Latest News for CNMD
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Wells Fargo 21st Annual Healthcare Conference, which is being held September 8-10, 2026 at the Encore Boston Harbor in Everett, MA. Management will participate in a fireside chat on Wednesday, September 9th at 1:30 p.m. Eastern Time. A live audio webcast of the fireside chat will be accessible under the “Events”…
Conmed's headline growth appeared flat at $343 million in the last quarter, but organic growth actually increased by 6%, with the leading segment being the orthopedic surgery business. Growth was offset by the divestiture of the GI business; as a result, growth metrics look poor with a quant rating of F and below the sector growth. When I adjust for organic growth, impressive profitability, and a buyback story,…
CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.
CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CNMD.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.